Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/8372
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZainul, Rahadian-
dc.contributor.authorYanuarti, Elsa-
dc.contributor.authorAmiroch, Siti-
dc.date.accessioned2024-11-25T07:15:18Z-
dc.date.available2024-11-25T07:15:18Z-
dc.date.issued2023-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/8372-
dc.description.abstractThis research explores the interaction of Masilinic Acid from the clove plant (Syzygium aromaticum) with the CD81 antigen to inhibit HIV virus regulation in silico. Using computational methods such as Pymol, Pyrex, and Protein Plus, we demonstrate that Masilinic Acid can significantly interact with the CD81 antigen. The obtained data shows binding affinities of -6.4, -6.2, and -5.7, and RMSD values of 0, 1.885, and 1.952. Further detailed interaction analysis with Protein Plus strengthens these findings, providing evidence of a strong interaction between Masilinic Acid and the CD81 antigen. This study also includes the testing of the Lepinski Rule of Five to assess the potential of Masilinic Acid as a drug candidate, with results indicating a mass of 472, three hydrogen bond donors, four hydrogen bond acceptors, a log P value of 6.2, and a molar reactivity of 134. These results indicate that Masilinic Acid has the potential as an inhibitor of the CD81-HIV interaction, which can be utilized as an effective antiviral strategy. Key words: Masilinic Acid, Clove plant, CD81 antigen, HIV virus, In silico.en_US
dc.subjectMasilinic Acid,en_US
dc.subjectClove plant,en_US
dc.subjectCD81 antigen,en_US
dc.subjectHIV virus,en_US
dc.subjectIn silicoen_US
dc.titleInteraction of Masilinic Acid from Clove Plant (Syzygium aromaticum) with CD81 Antigen in Inhibiting HIV Virus Regulation In Silicoen_US
dc.typeArticleen_US
Appears in Collections:VOL 15 NO 4 2023

Files in This Item:
File Description SizeFormat 
1.pdf804.1 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.